These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
128 related articles for article (PubMed ID: 2541285)
41. Induction/inhibition of chromosomal beta-lactamases by beta-lactamase inhibitors. Moosdeen F; Keeble J; Williams JD Rev Infect Dis; 1986; 8 Suppl 5():S562-8. PubMed ID: 3026004 [TBL] [Abstract][Full Text] [Related]
42. Comparative activities of piperacillin and tazobactam against clinical isolates of Legionella spp. Collins LA; Wennersten CB; Ferraro MJ; Moellering RC; Eliopoulos GM Antimicrob Agents Chemother; 1994 Jan; 38(1):144-6. PubMed ID: 8141570 [TBL] [Abstract][Full Text] [Related]
43. [In vitro activity of piperacillin-tazobactam against Klebsiella pneumoniae clinical isolates, producers or not of extended spectrum beta-lactamases]. Alarcón T; de la Obra P; López-Hernandez S; de las Cuevas C; López-Brea M Rev Esp Quimioter; 1999 Sep; 12(3):229-33. PubMed ID: 10878513 [TBL] [Abstract][Full Text] [Related]
44. [The effectiveness of so-called potentiated penicillins (augmentin and tazobactam) in vitro]. Blahová J; Hupková M; Krcméry V Cas Lek Cesk; 1995 Sep; 134(17):558-61. PubMed ID: 7553760 [TBL] [Abstract][Full Text] [Related]
45. Activity of amoxycillin/clavulanate against beta-lactamase-producing Escherichia coli and Klebsiella spp. Roy C; Segura C; Torrellas A; Reig R; Teruel D; Hermida M J Antimicrob Chemother; 1989 Nov; 24 Suppl B():41-7. PubMed ID: 2691485 [TBL] [Abstract][Full Text] [Related]
46. Beta-lactamase inhibitors and Acinetobacter spp. Eng RH; Smith SM; Cherubin CE J Antimicrob Chemother; 1990 Sep; 26(3):449-51. PubMed ID: 2172200 [No Abstract] [Full Text] [Related]
47. Mechanism of suppression of piperacillin resistance in enterobacteria by tazobactam. Kadima TA; Weiner JH Antimicrob Agents Chemother; 1997 Oct; 41(10):2177-83. PubMed ID: 9333044 [TBL] [Abstract][Full Text] [Related]
48. Tazobactam-piperacillin compared with sulbactam-ampicillin, clavulanic acid-ticarcillin, sulbactam-cefoperazone, and piperacillin for activity against beta-lactamase-producing bacteria isolated from patients with complicated urinary tract infections. Nomura S; Hanaki H; Nagayama A J Chemother; 1997 Apr; 9(2):89-94. PubMed ID: 9176745 [TBL] [Abstract][Full Text] [Related]
49. Comparative activities of the beta-lactamase inhibitors YTR 830, clavulanate, and sulbactam combined with ampicillin and broad-spectrum penicillins against defined beta-lactamase-producing aerobic gram-negative bacilli. Jacobs MR; Aronoff SC; Johenning S; Shlaes DM; Yamabe S Antimicrob Agents Chemother; 1986 Jun; 29(6):980-5. PubMed ID: 3015017 [TBL] [Abstract][Full Text] [Related]
50. [Evaluation of in vitro susceptibility of hospital bacterial isolates to piperacillin and tazocin (piperacillin/tazobactam]. Birawska I; Fuchs J; Szulakowska E Med Dosw Mikrobiol; 1998; 50(1-2):41-6. PubMed ID: 9857612 [TBL] [Abstract][Full Text] [Related]
51. Effect of conalbumin on the activity of Syn 2190, a 1,5 dihydroxy-4-pyridon monobactam inhibitor of AmpC beta-lactamases. Babini GS; Livermore DM J Antimicrob Chemother; 2000 Jan; 45(1):105-9. PubMed ID: 10629020 [TBL] [Abstract][Full Text] [Related]
52. Detection of extended broad-spectrum beta-lactamases in Enterobacteriaceae in four French hospitals. Legrand P; Fournier G; Buré A; Jarlier V; Nicolas MH; Decré D; Duval J; Philippon A Eur J Clin Microbiol Infect Dis; 1989 Jun; 8(6):527-9. PubMed ID: 2504594 [TBL] [Abstract][Full Text] [Related]
53. Piperacillin, a new penicillin active against many bacteria resistant to other penicillins. Fu KP; Neu HC Antimicrob Agents Chemother; 1978 Mar; 13(3):358-67. PubMed ID: 122519 [TBL] [Abstract][Full Text] [Related]
54. Susceptibility survey of piperacillin alone and in the presence of tazobactam. Acar JF; Goldstein FW; Kitzis MD J Antimicrob Chemother; 1993 Jan; 31 Suppl A():23-8. PubMed ID: 8383653 [TBL] [Abstract][Full Text] [Related]
55. Protection of piperacillin and ticarcillin from beta-lactamase hydrolysis by tazobactam (YTR-830) and clavulanic acid. Diver JM; Thornber D; Wise R J Antimicrob Chemother; 1989 Jul; 24(1):89-92. PubMed ID: 2550415 [No Abstract] [Full Text] [Related]
56. Use of a predictor panel to evaluate susceptibility test methods proposed for piperacillin-tazobactam. Bradford PA; Sanders CC Antimicrob Agents Chemother; 1993 Dec; 37(12):2578-83. PubMed ID: 8109919 [TBL] [Abstract][Full Text] [Related]
57. Variable susceptibility to piperacillin/tazobactam amongst Klebsiella spp. with extended-spectrum beta-lactamases. Babini GS; Yuan M; Hall LM; Livermore DM J Antimicrob Chemother; 2003 Mar; 51(3):605-12. PubMed ID: 12615861 [TBL] [Abstract][Full Text] [Related]
58. [In vitro synergistic activity of piperacillin-tazobactam combination against beta-lactam antibiotics resistant strains of Enterobacteriaceae]. Duex JM; Cordin X; Péchinot A; Siebor E; Kazmierczak A Pathol Biol (Paris); 1991 May; 39(5):374-8. PubMed ID: 1652728 [TBL] [Abstract][Full Text] [Related]
59. In vitro activity of AVE1330A, an innovative broad-spectrum non-beta-lactam beta-lactamase inhibitor. Bonnefoy A; Dupuis-Hamelin C; Steier V; Delachaume C; Seys C; Stachyra T; Fairley M; Guitton M; Lampilas M J Antimicrob Chemother; 2004 Aug; 54(2):410-7. PubMed ID: 15254025 [TBL] [Abstract][Full Text] [Related]
60. Antibiotic policy and prescribing strategies for therapy of extended-spectrum beta-lactamase-producing Enterobacteriaceae: the role of piperacillin-tazobactam. Peterson LR Clin Microbiol Infect; 2008 Jan; 14 Suppl 1():181-4. PubMed ID: 18154544 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]